Literature DB >> 25103822

Variation in mutation spectrum partly explains regional differences in the breast cancer risk of female BRCA mutation carriers in the Netherlands.

Janet R Vos1, Natalia Teixeira2, Dorina M van der Kolk3, Marian J E Mourits2, Matti A Rookus4, Flora E van Leeuwen4, Margriet Collée5, Christi J van Asperen6, Arjen R Mensenkamp7, Margreet G E M Ausems8, Theo A M van Os9, Hanne E J Meijers-Heijboer10, Encarna B Gómez-Garcia11, Hans F Vasen12, Richard M Brohet4, Annemarie H van der Hout3, Liesbeth Jansen13, Jan C Oosterwijk3, Geertruida H de Bock14.   

Abstract

BACKGROUND: We aimed to quantify previously observed relatively high cancer risks in BRCA2 mutation carriers (BRCA2 carriers) older than 60 in the Northern Netherlands, and to analyze whether these could be explained by mutation spectrum or population background risk.
METHODS: This consecutive cohort study included all known pathogenic BRCA1/2 carriers in the Northern Netherlands (N = 1,050). Carrier and general reference populations were: BRCA1/2 carriers in the rest of the Netherlands (N = 2,013) and the general population in both regions. Regional differences were assessed with HRs and ORs. HRs were adjusted for birth year and mutation spectrum.
RESULTS: All BRCA1 carriers and BRCA2 carriers younger than 60 had a significantly lower breast cancer risk in the Northern Netherlands; HRs were 0.66 and 0.64, respectively. Above age 60, the breast cancer risk in BRCA2 carriers in the Northern Netherlands was higher than in the rest of the Netherlands [HR, 3.99; 95% confidence interval (CI), 1.11-14.35]. Adjustment for mutational spectrum changed the HRs for BRCA1, BRCA2 <60, and BRCA2 ≥60 years by -3%, +32%, and +11% to 0.75, 0.50, and 2.61, respectively. There was no difference in background breast cancer incidence between the two regions (OR, 1.03; 95% CI, 0.97-1.09).
CONCLUSIONS: Differences in mutation spectrum only partly explain the regional differences in breast cancer risk in BRCA2 carriers, and for an even smaller part in BRCA1 carriers. IMPACT: The increased risk in BRCA2 carriers older than 60 may warrant extension of intensive breast screening beyond age 60. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25103822     DOI: 10.1158/1055-9965.EPI-13-1279

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  3 in total

Review 1.  Bias Correction Methods Explain Much of the Variation Seen in Breast Cancer Risks of BRCA1/2 Mutation Carriers.

Authors:  Janet R Vos; Li Hsu; Richard M Brohet; Marian J E Mourits; Jakob de Vries; Kathleen E Malone; Jan C Oosterwijk; Geertruida H de Bock
Journal:  J Clin Oncol       Date:  2015-07-06       Impact factor: 44.544

2.  BRCA1 and BRCA2 mutations in ethnic Lebanese Arab women with high hereditary risk breast cancer.

Authors:  Nagi S El Saghir; Nathalie K Zgheib; Hussein A Assi; Katia E Khoury; Yannick Bidet; Sara M Jaber; Raghid N Charara; Rania A Farhat; Firas Y Kreidieh; Stephanie Decousus; Pierre Romero; Georges M Nemer; Ziad Salem; Ali Shamseddine; Arafat Tfayli; Jaber Abbas; Faek Jamali; Muhieddine Seoud; Deborah K Armstrong; Yves-Jean Bignon; Nancy Uhrhammer
Journal:  Oncologist       Date:  2015-03-16

3.  Identification of Eleven Novel BRCA Mutations in Tunisia: Impact on the Clinical Management of BRCA Related Cancers.

Authors:  Yosr Hamdi; Najah Mighri; Maroua Boujemaa; Nesrine Mejri; Sonia Ben Nasr; Mariem Ben Rekaya; Olfa Messaoud; Hanen Bouaziz; Yosra Berrazega; Haifa Rachdi; Olfa Jaidane; Nouha Daoud; Aref Zribi; Jihene Ayari; Houda El Benna; Soumaya Labidi; Jamel Ben Hassouna; Abderazzek Haddaoui; Khaled Rahal; Farouk Benna; Ridha Mrad; Slim Ben Ahmed; Hamouda Boussen; Samir Boubaker; Sonia Abdelhak
Journal:  Front Oncol       Date:  2021-08-20       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.